Join the revolutionary fight against antibiotic resistance with a $5M investment opportunity in Andira Pharmaceuticals, the sole-recipient of a USPTO
Eligible investors now have the chance to participate in a Canadian health science company that is developing a brand-new generation of patented treatments for infections with medication resistance.
10 August 2023, San Francisco, California, USA GLOBEE NEWSWIRE An affiliate of US Capital Global, US Capital Global Securities LLC, has announced a $5 million investment opportunity in Canadian health research pioneer Andira Pharmaceuticals ("Andira" or the "Company"). The United States Patent & Trademark Office (USPTO) has informed Andira that it has granted US Patent Application No. 17/589,588 "Antibiotic Cannabinoid-Terpene Formulations." The patent has just one exclusive licensee in the entire world: Andira Pharmaceuticals.
The ground-breaking cannabis antibiotic from Andira is intended to work synergistically with daptomycin, one of the most often prescribed antibiotics in hospitals all over the globe, when administered together. Daptomycin resistance has grown significantly, which puts Andira's lead candidate AD02P3 in an extraordinary position to address the issue and restore the effectiveness of this heavily relied-upon medicinal therapy. Andira expects that by developing AD02P3 and bringing it to market, it can considerably increase the efficacy of daptomycin while eradicating antibiotic resistance.
According to Dr. Dana Lambert, President and CEO of Andira, "the allowance of this patent is a significant milestone toward successfully addressing hospital-acquired infections that are resistant to antibiotics." The antibiotic synergy between AD02P3 and daptomycin that we've seen is genuinely outstanding, increasing daptomycin's antimicrobial activity by orders of magnitude. We believe that clinical practice will quickly embrace this therapeutic strategy for infections that are resistant to treatment.
Charles Towle, COO and Managing Director at US Capital, said, "We are delighted to be supporting Andira in its pioneering work of revolutionizing anti-infective therapy." "Andira has a sizable international IP portfolio, and this USPTO issuance represents yet another important turning point for Andira. More than 20 different nations throughout the world have filed applications for the company's "Antibiotic Cannabinoid-Terpene Formulations," and more future patent allowances are anticipated in 2023 and 2024. The chance to participate in the Company's $5 million equity offering is now available to qualified investors if you're thinking about investing in Andira.
Concerning Andira Pharmaceuticals
A private healthcare firm called Andira uses natural medicine ingredients to enhance lives and treat serious ailments. The business is advancing critically important treatments for three fields of medicine: dermatology, cancer, and hospital acquired infections. www.andira.ca
About US Capital Global
The broker-dealer section of US Capital Global that is a member of FINRA and serves as a placement agent for growth-stage businesses, endeavors, and investment funds is known as US Capital Global Securities LLC ("USCGS"). Since 1998, US Capital Global has made a commitment to using cutting-edge FinTech and RegTech innovation to offer lower middle market businesses and investors sophisticated debt, equity, and investment opportunities that are typically only available to larger middle market companies and institutional investors. Entities under the US Capital Global umbrella administer direct investment funds and offer services for wealth management and capital raising. Visit www.uscapglobalsecurities.com/crs.html to view the USCGS Form CRS.
To learn more about this investment opportunity, email Lisa Terk, Senior Vice President, at lterk@uscapglobal.com or call +1 415-889-1026.
Attachment
- Andira Pharmaceuticals' US Patent Allowed
COMMENTS